Kiora Pharmaceuticals, Inc. (KPRX)
NASDAQ: KPRX · Real-Time Price · USD
1.880
-0.090 (-4.57%)
Mar 27, 2026, 4:00 PM EDT - Market closed
Kiora Pharmaceuticals Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
12
Market Cap
7.43M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | 16.02M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | 12.06K | -2.67M | -99.55% |
| Dec 31, 2019 | 2.69M | 1.03M | 62.54% |
| Dec 31, 2018 | 1.65M | 1.25M | 305.51% |
| Dec 31, 2017 | 407.52K | -261.74K | -39.11% |
| Dec 31, 2016 | 669.26K | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Bolt Biotherapeutics | 7.70M |
| Evogene | 3.85M |
| Aprea Therapeutics | 285.76K |
| Addex Therapeutics | 198.82K |
| Pulmatrix | 3.00K |
KPRX News
- 3 days ago - Kiora Pharmaceuticals Reports Fourth-Quarter and Full-Year 2025 Results; Company Advances Retinal Disease Pipeline with Two Active Phase 2 Clinical Trials - Newsfile Corp
- 5 weeks ago - Kiora Pharmaceuticals to Present at Oppenheimer's 36th Annual Healthcare Life Sciences Conference - Newsfile Corp
- 2 months ago - Retinal Disease Expert Dr. Taiji Sakamoto Joins Kiora Pharmaceuticals' Scientific Advisory Board - Newsfile Corp
- 4 months ago - Kiora Pharmaceuticals Granted U.S. Patent Covering Additional Formulations for the KIO-100 Family of Anti-Inflammatory Compounds - Newsfile Corp
- 5 months ago - Kiora Pharmaceuticals Reports Third Quarter 2025 Results; Company Advances Pipeline with Two Actively Enrolling Phase 2 Clinical Trials for Retinal Diseases - Newsfile Corp
- 5 months ago - Kiora Pharmaceuticals Joins RARE-X Vision Consortium Promoting Collaboration and Development of New Treatments for Rare Ocular Disorders - PRNewsWire
- 5 months ago - Kiora Pharmaceuticals to Participate in the 2025 Maxim Growth Summit and Eyecelerator @ AAO 2025 - Newsfile Corp
- 8 months ago - Kiora Pharmaceuticals Reports Second Quarter 2025 Results; Company Advances Pipeline with Two Active Phase 2 Clinical Trials for Retinal Diseases - Newsfile Corp